ArticleCurrent urology2025

Clinical evaluation of combined programmed cell death protein 1 inhibitor and poly(ADP-ribose) polymerase inhibitor in metastatic castration-resistant prostate cancer patients: Insights from a real-world study.

Yuan Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.